Bayer A.G. (BAYRY) Stock Price & How to Invest

Bayer AG is a Leverkusen-based life sciences company with three divisions. Crop Science (seeds, traits and crop protection, much of it inherited from the ~$63 billion Monsanto acquisition in 2018) is the largest by sales. Pharmaceuticals sells prescription drugs such as the anticoagulant Xarelto, the prostate cancer drug Nubeqa, the kidney and heart drug Kerendia, the eye drug Eylea outside the US, and the menopause treatment Lynkuet (elinzanetant). Consumer Health sells over-the-counter brands including Aspirin, Aleve, Claritin, Bepanthen and One A Day. Group sales were ~EUR 45.6 billion (~$51 billion) in 2025, and the primary listing is on Xetra in Frankfurt under BAYN, where it is a DAX member. BAYRY is a sponsored ADR that trades over the counter in the US, with four ADRs representing one ordinary share.

The investment picture has been dominated for most of a decade by the litigation that came with Monsanto, chiefly tens of thousands of US claims alleging that glyphosate (Roundup) caused cancer, plus PCB cases. Those liabilities, combined with Xarelto losing patent protection, pushed the shares down to multi-decade lows and forced the dividend to the German legal minimum of EUR 0.11. 2026 changed the tone: Bayer proposed a ~$7.25 billion class settlement in Missouri state court to resolve current and future Roundup claims over 21 years, and the US Supreme Court ruled 7-2 in the Durnell case that federal pesticide law preempts state failure-to-warn claims, a decision Bayer expects to lead to dismissal of many remaining warnings-based suits. The Xetra shares rose roughly from ~EUR 28 to the mid-40s over the past year (BAYRY from ~$8 to ~$12). What remains is a company with ~EUR 29 to 30 billion of guided year-end net financial debt, ~EUR 5 billion of litigation payouts in 2026 alone, and a pharma division that has to grow new drugs faster than Xarelto fades.

Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. Pharma faces continued generic erosion of Xarelto and Eylea, and pipeline setbacks (as with the earlier OCEANIC-AF failure of asundexian in atrial fibrillation) can reset expectations quickly. Crop Science is cyclical and exposed to farm economics, weather, trade policy and low-cost generic chemistry. Net financial debt near EUR 30 billion limits flexibility, and credit rating pressure would raise funding costs. For US holders of BAYRY there is also euro currency exposure, German dividend withholding tax, and thinner OTC trading than the Xetra listing.

4 analysts publish price targets on BAYRY, averaging $15.89 against a $12.47 price as of October 2026, or +27.4%. The published targets run from $15.30 to $16.68, a narrow spread, and the ratings split 3 buy, 1 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BAYRY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Bayer A.G.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Closing out the Roundup litigation. The single largest swing factor for Bayer is legal, not operational. The most optimistic published target, $16.68, assumes this works close to its best case.

The case against. Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. The most pessimistic target, $15.30, is roughly what BAYRY is worth if this bites instead.

Read the full bull and bear case on BAYRY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bayer A.G.'s investor relations page or your broker.

• Revenue (FY2025): ~EUR 45.6 billion (~$51 billion)
• EBITDA before special items (FY2025): ~EUR 9.7 billion; 2026 guide ~EUR 9.6 to 10.1 billion
• Core EPS guidance (2026): ~EUR 4.10 to 4.80 per share (new methodology)
• Share price: ~EUR 44 on Xetra; BAYRY ~$12.2 (4 ADRs = 1 share)
• Market cap: ~EUR 43 billion (~$48 billion)
• Net financial debt (2026 guide): ~EUR 29 to 30 billion

At ~EUR 44 a share, Bayer trades at roughly 9 to 11 times its 2026 core EPS guidance and around 7 to 8 times enterprise value to EBITDA before special items, a discount to large European pharma and agrochemical peers that reflects leverage and residual litigation risk. Reported net income has been negative (a net loss of ~EUR 3.6 billion in 2025, driven by litigation provisions), so trailing P/E figures on data sites can look meaningless or distorted. The dividend has been EUR 0.11 per share, a yield well under 1%, while cash goes to settlements and debt reduction.

Other names that sit close to BAYRY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BAYRY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BAYRY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BAYRY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BAYRY gives US investors dollar access to Bayer's mix of crop science, prescription drugs and consumer health, a business whose valuation in 2026 hinges less on its products than on how cleanly the Roundup chapter closes and how quickly the balance sheet heals.

Whether BAYRY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BAYRY a buy or a sell?, and where the stock could go from here in the BAYRY stock forecast.

For income investors, whether BAYRY pays a dividend and how the payout looks is covered in does BAYRY pay a dividend? And to weigh BAYRY against a peer, read the full side-by-side comparisons: BAYRY vs CTVA and BAYRY vs BASFY.